МЗ России, Иваново 25ГБУЗ ДЦ № 7 (глазной), Санкт-Петербург 26ФГБНУ НИИ ГБ, Москва 27ГУ РНПЦ РМ и ЭЧ, УО ГомГМУ, Гомель, Беларусь Степень ком-пенсации офтальмотонуса была рассчитана согласно официальным рекомендациям РГО (2015) об опти-мальных


Чтобы посмотреть этот PDF файл с форматированием и разметкой, скачайте его и откройте на своем компьютере.
œÄ•—††ƒ ††–
\t\f \f  \n\b
\t\f \b 
  \t\f
\r\n\f. \b 1.  \t\r
\b

 ­€‚
­ƒ„
 …†
‡ˆ
 ‡„
‰ ­
Š‹ŒŽ‘
Š’„’“
Š „Œ
Š”­­
ŠŒ‘
Š„•„–
Šƒ€„•
†—†
†˜­ˆ™
š€­„–
š„
š›Š
†™–
œ„Œž
œ­“
œƒ
Ž„‚
ŽŸ•†‡
‘ •¡
š‘
›ƒ—„–•ƒ­›
‚ˆ
‡­ˆ“
‚„ ‹¢›
‚ ’
£¤„Ž
ž€Œ‚
¥ ‚
¦ 
¦•ƒ­
Æ­Ë›œÌ›Ì­È¡‡‡Ë\r™

Æ•­œÇÙÌ•­šÌÈÉÈ›“Æ™
\b\t
­•Ëꇝš\r\r™
\b\t
­›ËœæÇÈ›•Ëš¡ËÉ™
\b\t
Æ­›œÌ›•­Èœ™
ˆ\b\t
Æ­¡œȇ”•È­‡Æ\r\r \t™
 \t\b\t
­Ëœæ›•›Ë”á\rž\r\r™

Æ­Ë›œÌ›ƒæ­ÈœÈ\r™
\t—
Æ­ËœÇÌ\r\f\f„\r\f\b\r\f
ÉÈæ“Æ™
‰ƒ
Æ­Ë›œÌ›•­Èœ\b\rÌÆÌ\r\f\rƒä„\r\r™
ˆ\b\b\t
›\n\n\r„ê™\r\r™
\b\t
‡œæÇÄ\r\r\n\r„É
›¡›Ç“ØÄÉ™È\r\r\f„È\r™
\b\b\t
­Ëœæ›•Ëꙍ\nÅ
­ËœæÇ­\r\r\b\rê‘ŸÉ™
\b\t
ÈÆœšÇÈ„\f„LJ\r\rÉ™
\b\t\n\b­
•\ršǎúÖ»‹¼ºÒÃÉ™
Ž‘\t‰\t\b
­¡œæ“•›ËÈæ“”™
ˆ­
­Ë›œÄš›•­È¡™
ˆ­
›\r\rÇ­•É™
\n\b‰\t\b
Æ­Ë›œÌ›“‡Èœ‡š\r\r™
\b\t
•­Ëœæ••›•Ëš­È\r™
ˆ\b\b\t
Æ­Ëœȇ­Ë­\r„™
\b\t
Æ­Ë›œÌ›­È¡™
‡\b\t
Æ­Ë›œÌ›­È¡Èæ“\r™
 
­ËœæÄÙê† \r\f\t™
\t—
ƭˇœ‡­Ë™
\b\t
­œ“‡šÙ“È’™œ›­\r­Èœ™
\n­\n\b­
¡›•\f›Çæ\b\rɇ­Ë™
ˆ\b
•­ËœæÇÌ•ÄÙÉ™
\n\f\b\t
Ù•æÇ”\r¡É™
‚\f
š\r­\r\r\rƒ\r
ǝ\r\r\f\b\r\rˆÉ™
ˆ‘\n\f
ƒ‘’““”•–’”—‘˜”——’—™„ˆŽ  šˆŽ 
\rŠ\n€\nƒ\bŠŠ\f\b\b\n\fŠ\b\b­
ˆƒ\n\t\bÐ\b\b
 :
¡“Ì™¡\r¡™Ë‡¡™ËÄ¡™Ë¡ñ
\r\b\r\r\n\r\b\r\f\r\r\r\r\f\r\r\f
\b\r\r\n\r\r\r\b\r\f\r\r\rÎÎ
Ì\n­‚
\n\n\t
Ÿ –ņ \t˜ƒŸ–
 €€:
… \n€… ­…†„
, e-mail: [email protected]
\f \n \t\f \f
2018, Š. 17, ™ 1, . 14-28
Russian journal of glaucoma
2018, Vol. 17, ™ 1, pp. 14-28
\f   : 28.12.2017
Received for publication: December 28, 2017
ŠŠÚ€‚\fÛ
Í»º˜ Ÿ‘†  Î¿Ï½Ÿ –  Ÿ
\r€‚\r
ˆ\f \f \f  \f\n
\f    \b\f
 \b\f   \n \f \n \f\n
(ˆ“„).
\r.
­ \n \f \b
\f -\f 
  \f,   
   \f 2017 .  30 -\f
\b 6 (†)  (ƒ\f , €, €,
\f, , “\b), \b\f \f 
136 \f (237 \f; \t — 52 (38,2%), \tŽ —
84 (61,8%)).   ‘ \b\f  
\n \f   \b\f  \t
  \f. ­  \f  \b\f
\f    \n \f
\n  \b\f\n  \t 
\f   \f.   \f
 \f \f \f\f  
\f    \b\f \f
\nŽ\n \f \f  \f\f
    
\f \f (­„…) ( \f,  10 ),
\f   \f 
\f\n.
\f\r\n.
 \b\f   \f
 \b\f \f    
ˆ“„ \b\f     \f  
 4,3 (3,7; 5,8) .  \n  \b\f
\f   \f \n  73,37% \f,
 19,02% — †\f  ,  4,35% —  \f
††,  3,26% —  \f  ; 
 \f  59,52% \f, †\f  \f
†† —  33,33%,  \f  —  7,15% \f
; \f ††  \f  54,55%,
†\f  \f  —  45,45% \f  
 5 \f. “ ­„…   \f  \b\f
      ˆ“„ 
 \f\f (p=0,557, H=2,073)  \f\f  
19 (17; 21)  .. ­ \f  \f†    -
\f \n \n ˆ“„  «†»
 ­„…   \n
\f \bŽ („ˆ)  \f 
\f \n  \f,      
 \n, \f ††\n  \f \n 
ˆ“„ ‘ \f  †. «ˆ\f \n»
 ­„…     \f\f
(p=0,597, H=1,882)      \f
  \f\f   19,5 (18; 21)  ..,
  «\f» ­„…    
\f \f   (p0,001; H=32,175).
…\f   \f \n \n ˆ“„ \n
\t  \f \b\f ‘, \f «
» \f \f \f† 2,17%. “   
\n \n \n Ǡ
\n»  ­„… \f  38,1% ,  \f
††\n
 —  81,82%. \f  
 \n   \b\f \f,
 MD \f \f\t\f    29,5% \f,
  70,5% \f  MD \b\f \f \n.
\n \r\t\b\r.
­ \n \b \b\f \f 
 \f    \f
\fŽ, Ž  \f
  \f  : «
†\n»  ­„…, «\f \n» 
­„…, «\f\n»  ­„…. \f  
\f  \b \f  \f 
ŽŽ \f \n  \f
  \f «†\n» 
­„…  \b   \t  \b\f
.
 \r­\r ­\n:
\f, \t \f, «
†\n»  ­„…, «\f \n» 
­„…, «\f\n»  ­„…, 
\b\f.
Comparison of treatment regimens for patients with primary
open-angle glaucoma with signs of disease progression.
Part 1. IOP levels
§¨\f\f©
§ª\f«\n¨ §¬
\b®\n¯\n§
\fª\t°§
 \f±\r\n\f§²®
ª\b
³´¨ \b\rµ\n¶·
³±¯±¸©
³ª¯µ§
³ \b\f\n\b
³\fµ\n§·
³ ¨\n¯¹\r\t
³®º \f¯¹\r§§
° »\f\f°§
°\t®\b \f²¼
½¨º\b\t\r
½\b\r¯¨§
½\f \f¾³
†™–
¿ ¯µÀ©
¿\n¨ \b¸
¿® \t\f¨§
¶\n¯\n¬
¶Á¹\r\f°±\r
·ª¹\r\nÂ
 \n½·
¾\n®» ¯\t¹\r®\b¾
\f ¬²®
©±\r\b²®¸
¬\n¯ª´\t\f½\r¾
¬\fª\f±\n\f§
Ãº\r¯¶
Àºµ\n¬
ª±\r\n¯\n§
¿\r\rª§¬
¬\r\b\rª§
¬\f¹¯®¹©
\b\b\n\t\n€
Ó®¬³¯²À°°¬°²¯Á¦Ž¨§¨¯Ò¯³©ª§µÕ²©´¯¬«©¨£™
¡¦›¦œš´™
Ò§²³¬£À§¸¯²¨¬§µ¸µ©²©ª§µÔ°«¥©¨§µ™
º¦½¼¦Ù
‹©¬°¹°´¸©¨£
Ž¨§¨¯¸µ©²©ª§µÔ°«¥©¨§µ¿™
º¦½¼¦Ù
Ó§£§²³©²Ò®¬¤§²«ÀŒ¯¹©°²§µ¸µ©²©ª§µ»¥¦¨¦§µ¤°µ°¹£Ô°«¥©¨§µ™
º±›¸¤œ½Ÿ
Ž¨§¨¯Ò¯³©ª§µÕ²©´¯¬«©¨£™
±›½Ÿ
¼¦¯º¬À®¨«ÀÓ¬§²ª¦°±¨¦¯Ö¯³°¬°´‰£¯Ò©ª¬°«®¬¹¯¬£Ž¨§¨¯Ö¯³¯¬§µº²«¨©¨®¨©°²™
»›Ÿ±¥½Ÿ
‰¬°«¦¯´«À£Ž§¤§¬§Œ¯¹©°²§µ¸µ©²©ª§µ»¥¦¨¦§µ¤°µ°¹©ªÔ°«¥©¨§µ™
°¤¸¤›¤
¿°¬¨¦ƒå¯«¨Ö¯³¯¬§µÒ¯³©ª§µ§²³Œ¯«¯§¬ª¦¸¯²¨¯¬™
°¤²œ¥—©š¥š›½·±›£
õµƒŒ®««©§²‰£¯§²³‹µ§«¨©ªŽ®¬¹¯¬£¸¯²¨¯¬™
þ¤
°£²°ƒÝ§«¯²¯¨«À£߬§«²°£§¬«À£Ž¨§¨¯Ò¯³©ª§µ
Õ²©´¯¬«©¨£™
›¤½œ¦ž¤›½Ÿ
Œ¯¹©°²§µ‰£¯Ô°«¥©¨§µ™
¢›ž¤œ½Ÿ
Œ§©µ·§£¸µ©²©ª§µÔ°«¥©¨§µ°±¨¦¯ÇŒ®««©§²Œ§©µ·§£«É™
¸¯²¨¯¬°±‰£¯Ò©ª¬°«®¬¹¯¬£™
¨¦§¦½²·²›½Ÿ
‹®¶µ©ª¸µ©²©ª§µ¸©¨£Ô°«¥©¨§µ¿™
˜™š®ž¤·²œ½Ÿ
Ž¨§¨¯¸©¨£Ô°«¥©¨§µ¿‘Ÿ™
º¦½¼¦Ù
Ò¯³©ª§µ¸¯²¨¯¬󿯷©«©°²ó™
º²œ½Ÿ¢š®¤›±½
ǎúփ»‹¼ºÒÃɉ£¯Ò©ª¬°«®¬¹¯¬£¸µ©²©ª™
Ƥ½™Ÿšœ¥ô·šŸ²½¥¤œ
Œ¯¹©°²¸µ©²©ª§µ»¥¦¨¦§µ¤°µ°¹£Ô°«¥©¨§µ™
¤´¤œ
Ž¨§¨¯Ò¯³©ª§µ꧳¯¤£™
¤´¤œ
Œ¯¹©°²»¥¦¨¦§µ¤°µ°¹£Ô°«¥©¨§µ™
¶±®²½¥¤œô·šŸ²½¥¤œ
‹©¬°¹°´Œ®««©§²¿§¨©°²§µŒ¯«¯§¬ª¦Ò¯³©ª§µÕ²©´¯¬«©¨£™
º¦½¼¦Ù
Ò§À§¬°´»¥¦¨¦§µ¤°µ°¹£¸µ©²©ª§µ
Ô°«¥©¨§µ™
›¤½œ¦ž¤›½Ÿ
Ô¯µ¤¹°µ¨ÁŽ¨§¨¯Ö¯³¯¬§µŒ¯«¯§¬ª¦»¥¦¨¦§µ¤°µ°¹£º²«¨©¨®¨¯™
º¦½¼¦Ù
Ž¨§¨¯Ò¯³©ª§µ꧳¯¤£™
Ž¨§¨¯Ò¯³©ª§µ꧳¯¤£™
»§¤œ¦§¦
»¥¦¨¦§µ¤©ªÍ©§¹²°«¨©ª¸©¨£¸¯²¨¯¬ꆙ
°¤²œ¥—©š¥š›½·±›£
Žª©¯²¨©±©ª§²³Œ¯«¯§¬ª¦
Ž¨§¨¯Ö¯³¯¬§µ»¥¦¨¦§µ¤°µ°¹£º²«¨©¨®¨¯™Ò°«ª°·Å
Ž¨§¨¯Ô°«¥©¨§µ™
¶¦¸š®¢š®¤›±½
ߧÁ§À¦Žª©¯²¨©±©ªƒŒ¯«¯§¬ª¦º²«¨©¨®¨¯
°±‰£¯Í©«¯§«¯«™
ª®¸¤¥ž¤´¤Ÿ™½¥¤œ
‹§ª©±©ªŽ¨§¨¯Ö¯³¯¬§µÒ¯³©ª§µÕ²©´¯¬«©¨£™
¡®¤«²§¦½¥¦Ÿ
Ò¯³©ª§µ¸µ©²©ª§µ¸¯²¨¯¬
Ǽ°²®«䧬©«É™
¨²´™œž¨¦§£¦›¦«
‰¤¯¬¹¯²ª£Ò¯³©ª©²¯º²«¨©¨®¨¯™
˜™²½²œ¤±º¦®«¦§¤
˜¦œ¾®²¼¥½¦¾»œ¥š›š½¥¤œ«°¦±›¼š¦¾¿±œ«²œ£Ðœ¦œš«š¼®¤›š«
For citations:
ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ™Ó§À®²©²§¿Ã™Ó¯µ§£§ÍÙӬ¯Á¦²¯´ÃÝ®¯¨§µ¸°¤¥§¬©«°²
°±¨¬¯§¨¤¯²¨¬¯¹©¤¯²«±°¬¥§¨©¯²¨«·©¨¦¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§·©¨¦«©¹²«°±³©«¯§«¯¥¬°¹¬¯««©°²
‹§¬¨º»‹µ¯´¯µ«
¨¤¥½²¦œ¤®Çœž²´™±›œ¤®£®¤±Ÿ¦¸¤
Ÿ –ņ \t˜ƒŸ–
Abstract
PURPOSE:
indicators on disease progression in patients with primary
open-angle glaucoma.
This combined, analytical scientific and clini
January and April 2017. A total of 136 participants (237
eyes) from 30 academic referral centers from 6 (six) coun
tries (Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia,
Uzbekistan) were enrolled — 52 (38.2%) males and 84
(61.8%) females. As a first step, glaucoma anamnesis
ated. Glaucoma was diagnosed according to the differential
cases. All data concerning the stage of disease were veri
fied repeatedly at the start of the study according to the
current glaucoma classification and with additional IOP
and functional indicators research.
RESULTS:
The history of the disease at the time of the
final examination for patients with different stages of glau
coma was comparable in time and averaged 4.3 (3.7, 5.8)
years. Over the average follow-up period, the initial stage
did not progress in 73.37% of mild glaucoma cases, 19.02%
of cases have progressed to moderate glaucoma, 4.35%
have progressed to advanced glaucoma, 3.26% — to ter
minal glaucoma. Moderate glaucoma stage was preserved
in 59.52% cases, in 33.33% it progressed to advanced glau
coma, in 7.15% — to terminal glaucoma. Advanced glau
coma stage remained without a progress in 54.55% cases,
in 45.45% cases it has progressed to terminal glaucoma
during 5 years. Mean IOP level after follow-up period was
19 (17; 21) mm Hg and had no significant difference (p=0.557,
H=2.073). Consequently, only in early-stage glaucoma cases
the average «inter-visit» IOP value corresponded with va-
glaucoma) it was significantly higher. There was no significant
in patients with different glaucoma stages, and «intolerant»
IOP-level increased from stage to stage (p0.001, H=32.175).
The initial regimen was generally effective for patients with
mild glaucoma with IOP level increase registered only in 2.17%
cases. «Inter-visit» IOP-level was above recommended values
in 38.1% cases in patients with moderate primary open-angle
glaucoma, and in 81.82% in patients with advanced primary
open-angle glaucoma. The analysis of visual field change
during the follow-up period showed that MD increased in
29.5% cases and decreased in 70.5% cases.
CONCLUSION:
In this paper we assessed IOP level not
terminology, such as the «inter-visit» IOP-level, the «opti
mal» IOP-level, the «intolerant» IOP-level, to characterize
the IOP dynamics in different time intervals. The results
of the study suggest that inter-visit IOP range can be one
of the possible predictors of glaucomatous damage, and
therefore can be useful for correction of existing clinical
KEYWORDS:
glaucoma, treatment regimen, the «inter-
visit» IOP-level, the «optimal» IOP-level, the «intolerant»
IOP-level, disease progression.
ŠŠÚ€‚\fÛ
\r\r\r\r š›œ­\t
\fž\f\b\r\n\r\f\r
\r\r\r\r™‚ˆ\f
\r\r„\r™\r\r„\rƒ…\r\r
\rП™ÑÌ\r\b\r
\r™\r\f™\r\r\b\r‚ˆ\f
\n\r\r\n\r‚\r
\r\r\f\r„\r\r\r\b\r
\r\r\r\f\b…\r\r\n\r
\r\f„™\r\nˆ
\r\r\r\r„\rА™ Ñ
á\r\b\r\r\b\r
\b\r\r\n\r\n„\r\r\f\r\b\r\f
\f\r\b ­›‡\t\b\r
\r\r Ì­Ä\t™\r\r\r\r\n\r
\r\r™
\b\r\r\nБ™—™–™™†™ŸÑÌ\r\f
\n\r\rƒ\b\r\r\f\b
š›œ­\n\r\b\r\r\b\b
\b\r\r\f\b\rˆ„
\r\r\f‚ˆ\r„\f“\r\f
\r\r\r\r\r\r\nˆ “­›\t™\r\r\r\r
\n\r\r\r\f\b\r\b\r
\r\r\r\f\n\r
\r\r\rÌ
\r\r„\r\r\f™\b\r
\b\r„“­›“\r\b\r\r\r
\b\r™‚\r\r\r
\rž\r\b\r\r\rž\r
\r\f\b\r•\r\r\r™\r\rˆ\r
™\r\b‚ˆ\r
\r\r\b\r\r\r\n\r
Ì…\r\f\n\r\r\b\r\r\r\r\r
\b\r\r\r\r\n\r
\r\b‚ˆ\b
\r\b\r\r\r\r\r\n\rƒ
\r\r\r\b\r„І™Þ™Ÿ‘ƒŸÞ™™™Ñ
Ù\rˆ\r\rÊ\r\b
\r\b\r\f\r\r\r
\b\r\r\n\r\n\rš›œ­
ƒ \r  \r \f
Ì\r\r\f\b\r\r\r\r\n\r\r\r
\r\r\rƒ\r\r\r\r„\r\r\r
\r\r\r\r\r™\b\r\r\r\b\r
\b\r\bŸ †\r \rƒ
\n— ž\t Ë™•™
•™È\r\r™“\r™œ\n\t™\n
‚—\r Ÿ†ÅÊ
‘Ÿ –™ŸÛ\t™ˆÊ– —™–Û\t\t™\r\r\r
†‘Û\r\r\nˆ\r\b\r\r
›„\r\f\r\b\r
\r\r‚
\r\rž\n\n\r
™\r\f\r\r\b
\r\n\r\r\r\f \r\r\r
\tÄ\b\r\n
\n\b\r\r„\r\b
\r\r\r\r\r\r\r½°°¹µ¯
Ò©ª¬°«°±¨ \r\nʁã¡\t\b\r\f\r
\r\r\f\r™‚ž
\r\f‚ˆ\r\r\rœ
\b„\r\r\n\r\b\r\r
\b\r
‡\b\r…\b\n\b\r\r\b
\f\n\r
\r\b\r\r\r\rš\r\b\rÇÉ
\b\r\r
\r\r™\r\r\r\r™\b\r
\r\n\rƒ\r\r\r
\b\r„\r\b\r
\r\r\b…\r\r\r\f
\b \b\b\r\b\b\r
\r\n„\t™\r\r\r\r
™\b…\r\b\r\r\r\r\r\r
\b™\b\r
 \t„\r\r\b\r\r
™\n\rÌ\r
\n\r\b\r\r \t\b\r\r
™\r\r
\r\r\r\n\r
Ì\r\r\n\r\r\r
\r\f„\r\f\r
\n\r\f\b\r\b„\r
\r\r\r
\b\r\r\r\r\n\r
\b\r„\r\f\r
„ \r\r\r\r™\r\r
\r\b\r\b\t‡\r
‚\r\b\r\r\r\b\r
\r„
\n\r\r\r\f‚ˆ\f„
\r\r\b\r\r\r
\r\r\rÌ­Ä \b\rÈ\r™\r \t™
\r\r\r„\r
\b\r\fš\r\r
\r\r\r\b™\b\r
\r\r\r\r™
\r\r\f\r
‚\rÌ\r\r\r
\r\rÌ­Ä\r\r
\rÞ\rŸ\r\b\r
\b„\r\r\r\n\r\r
\r„\r„“­› Ÿ ‘\t\r\n\r\b
„\r
\r\r\n\r\r\r\f\r
š\r\r\f\r
\r\f\b ¡š\t\r\b
\r\r ÒÍ\t
\r\r\r\r ‹ŽÍ\t
\rž\b\r\b\r\r
\r\r\b‚\bÔ®¤¥¦¬¯£† ©
†‘ © Ǹ§¬µ««Ò¯³©¨¯ªº²ªÉ™ã¡™\b\r
Žº¼Ã¼¦¬¯«¦°µ³™ ƒŸ\t»ª¨°¥®«Þ   ÇÔ§§¹ƒŽ¨¬¯©¨É™
Ž·©¨Á¯¬µ§²³™\b\rŸ™½\t
\b\b\n\t\n€
œ‘‘žž
ˆ\t\n„€Ð
\b„\r\b\r\r\f
\r\f™\r\f\ržž\f
š›œ­ \b\r…\r\r
\r š’\t\n\r™\r\f\b‚\r
\b\f œš•\t\t™\r\r
\b\r\b\r\r\r‚  Ÿ †\r™
\b…\r\r\n\rƒ\r\r\r\b\r„
\r\r\n\r\r\r\r\r\f
 \b™\r\r\f\b\b
\b\b\r‚™\b\r\r\r\r\b
\r\n\r\r\f\b\r\b
\r\r\rΏ\r‚
\tÅ\r\r\r\r\n\r\b„
\r\b\r‚\n‚\r‚\b\r
‚\b‚\b\r\b\r\b
\r\b\r\r\f\r\r\f\r\b
„Å\r\b„\rÊ\r \r–Þ \r\r\r\f™
\b\r\r\f\f\r™\r\r
„Ì\r\f›„æ\r\r
\rŸ Ÿ™····¦°©²¨Î¬®\tō
„è—™ \bè™ \b
•‚˜\b„‚\n\r\f
\r\f\r\r\fš›œ­\r\f„\f™
\ržÅ\b\r
\r\b™‚ˆ\b\r\r
\r\r\b\r\r
\r™\b\rˆ\b\r\f
\r\rÅ\b„‚\n
\n\r \b™\r
\r\r™\rʍ\r
\r\r\f™\b\r„ÃŒ‰ÍŽ Ÿ  \t™
\r\r\b\r\r‚\f\r\r\f\n
\r\f\r\b™\r\r™
\r™\r\r
€„\f\b\b\n\r\r
\tÅ\b„\n\r
\r™‚ˆ\b\r
\r\rÅ\b„\b\r\b\r\r\f
\b\r\f…„™Ç
\r\fÉ…\b\r\f…„
\r…„™\b\ržž\r\r
 \b™\b\r\r\r\r
™\r\b\r\r\b
„\r\r\r\n\rè\b\tÅ\b„
‚\n\r\f\r\r\f\r\r\f \r\b\r
\r\b\r\tÅ\b„\r\nˆ
\t\n\r™\n‚ˆ\r\r
\r\f\b™…\r\b\r\r\r\r
\b\r\r\fÊ
¦¨¨¥«˜ÎΪµ©²©ª§µ¨¬©§µ«¹°´Î
Ÿ—¡
›\n\n\r\b\r\b\r\r
\r\r\b\r\r\b\r
Ž¨§¨©«¨©ª§ –™ ™Ž¨§¨Ž°±¨º²ª™ã¡\t\b\r
‚ˆ\f\r\f\b\r\r\f\b\r
\r\r\n\r
š\r\b™‚ˆ\r\r
\b™\b\rÈ褙ÈÊ
™¤Ê\rž\n
\r“\b\r\b
\r\b\r\r\råƒ
ã\b\r眚™‚ˆ\b
\r\r\r\r\r\r™\b\r
ȯ í
Åí
†‘Û
\t™ȯÊ™í
í
†‘Û
Ê
š\r\r\b\b
\r\b\b
\b\r\r\b\b\r\f\b\r\r
¨ƒ\f‚š\r\r\r\r
\r\r\b\b\r\b
\r\n\r\r\b\r\r
\b\r\b\r\r
\n\r\rÊîƒ\b\b\r„ÕƒÈç
œ™\b\r\r\b\b\r\f
\bîƒ\b\b\r„¼ƒÌ\r
\rč\b\r\r
\n\r\r\bÔƒ\f•çœ\r
•\f\r\r\b\b\r
\b\r\bé ™ ‘
\r€  
\f\r\b„\r\r\r
\r\r ™\n
\b\r\b\b\t\r—™   ‘Þ™‘Å—–™‘\t
\r™\r\r\r\r\n\rÊ
—Þ™   —™— Å†™† \t”\r\n\r™
\n\r\r\r\r\r\n\r
\b„\r\r\n
\r\b\r\b\r\r™ 
™† Å‘™– \t\r
ҁ\nÍÓ
‡\n\r\r\r
\f\b\r\r
ˆ ¥õ ™ ‘\tÌ‚
\r\b„\n\f\r
\r\b\r\n\r‡\n\r\r\r
‚\b\b\r\b„\r\r\f™
\r\r\r\f\r\f\n\r
²Ú–™††™—Û\t™ˆ\rž\b\r\b
\bÊ\b„\r\f ²ÚŸ™†™†ŸÛ\t
\ržž\f ²Ú™™—‘Û\t\r
\nÏ
\b\b
\r\r\r\r
\r\r\n\r
š\r\r\b\r\r\r
\r\r\b\r\r\r\nˆ\b\r\f
„\b\r\r\f\b
™\r\r\b\r\r\r\f\b\r
\bÒÍÊ\b\b\r\r
\r\r\n\r\f
Ž\nÏ
‚
ž\r\r
\r\r\r¡\r\r\n\b\r
\r\b
\r\r\r\r\r\r
\r\n\r
ҁ\nÉÓ
ŠŠÚ€‚\fÛ
\r  
\f  ­
Age at diagnosis verification
\r  
\b \n\f
Age at final examination
\b\b
 ­
POAG duration
\t/
n=52
62,28±1,14
63,6 (56,85; 67,70)
67,37±1,14
68,1 (62,2; 73,60)
4,55 (3,90; 6,20)
’Ž/
women,
64,63±0,72
64,85 (60,3; 68,70)
69,48±0,72
69,15 (65,6; 74,30)
4,2 (3,50; 5,65)
C 
Statistical significance
, p/U
p=0,131
U=-1,511
p=0,177
U=-1,350
p=0,180
­/
Total
, n=136
63,73±0,63
64 (59,35; 68,15)
68,67±0,63
69 (64,60; 73,70)
4,94±0,16
4,3 (3,70; 5,80)
\f\f 1.
\r   \r \t€\f   \f 
   \t\f \b \n\f, n=136, ‚±m, ‚e (Q25%; Q75%), 
Table 1.
Age characteristics and anamnesis at the diagnosis verification and at the final examination
timepoints, n=136, ±m, e (Q25%; Q75%), years


\b
Mild POAG,
ƒ\r\f
Moderate POAG
 \r„„
Advanced POAG

\f\b
Statistical
significance
, p/U

Total
n=237
-2,67±0,11
-2,56
(-3,96; -1,62)
-7,64
(-9,75; -6,56)
-14,63±0,75
-14,21
(-16,70; -12,28)
  \f,
..
\n \f —
 
no significance, since
different disease stages
serve as inclusion criteria
-3,22
(-5,37; -1,91)
PSD
3,08±0,11
2,76
(1,92; 3,80)
5,61
(4,39; 7,14)
9,04±1,14
10,18
(5,74; 12,56)
0,001
=-7,107
0,001
=-4,857
=-2,281
3,87±0,16
3,16
(2,09; 4,81)
\f\f 2.
  \t   \f ,
n=237, ‚±m, ‚e (Q
Table 2.
n=237, ±m, e (Q
:
0,001, U
=-7,107
—  \n  \f\n \t \f \n  \n  \f;
0,001, U
=-4,857 —  \n  \f\n \t \f \n  \f ††\n  \f;
=0,023, U
=-2,281 —  \n  \f\n \t \n  \f ††\n  \f.
Note:
1,2
0.001, U
1,2
=-7.107 — statistical significance between mild and moderate POAG; p
1,3
0.001, U
1,3
=-4.857 — statistical significance
̍\r\b\r\r\r\r\r
\b\r\r\r\r\f\r
žž\f\r¡\n\r
\r\r\r\r\n\r\b„\r
\r\n\r\b\r\b\r
\r™Ÿ  ™† Å‘™† \t\r
ҁ\nÔÓ
æ\f\b\r\n‚™Ÿ\r
\r\r\r\f‘ †™†Û\t–
\b„\r™‘ Þ™ ŸÛ\tÊ\bž‚™–
™‘Û\tÊ\ržž‚™— ™Ÿ—Û\tÊ
‚‚æ\r\f ™Ÿ\r\t\b\r
\n‚\r\r
Ÿ‘ ‘Þ™‘ŸÛ\tŸ\b„\r™\bž\r
žž‚ʐ ™Û\t™‚Ê
†™‘Û\tÌ\r‚\r™\ržž
\r— ‘™‘‘Û\t\b„\r™\bž
‚Ê‘ ‘™‘Û\t\b\r‘
Ì\r\r\n‚\r\r
\b„\r\f\rˆ\r\f\r\r„\r\b
\r\f\r Ù”“\t™\r\n\r\r‚
\rž\n\b\r„\r\r\r’
\b
\nÕ
š\r\rˆ\r\r„„
\r\f\r\b\r\f\r\r\r\r\r
\b„\rš›œ­ ¥Ú ™—Å
\b\b\n\t\n€
   \b \n\f
Disease stage at the final examination
\b
Mild
ƒ\r\f
Moderate
 \r„„
Advanced
…\b
Terminal

Total

 
-

\f
stage
\f  
mild
4,72±0,14
4,20 (3,60; 5,40)
5,43±0,34
4,80 (3,50; 6,90)
4,45 (3,35; 5,20)
4,70 (4,20; 6,30)
4,90±0,14
4,20 (3,65; 5,75)
 
moderate
\t
impossible
4,10 (3,50; 4,70)
4,75 (4,20; 6,30)
5,27±0,84
5,10 (3,90; 6,80)
4,85±0,27
4,20 (3,60; 5,40)
\f ††
advanced
\t
impossible
\t
impossible
4,65 (4,20; 5,60)
5,40 (4,70; 6,50)
5,00 (4,2; 5,8)
\f 
terminal
\t
impossible
\t
impossible
\t
impossible
\n
\f
exclusion
criteria
\n
\f
exclusion
criteria
­
Total
4,72±0,14
4,20 (3,60; 5,40)
4,15 (3,50; 6,55)
4,7 (3,70; 5,70)
5,15 (4,20; 6,50)
4,89±0,12
4,2 (3,70; 5,70)
n=237
\f\f 4.
\r \r\n\f \f \r\f      \n
\r\n\f  \t\f \b \n\f, n=237, ‚±m, ‚e (Q25%; Q75%), 
Table 4.
Disease anamnesis according to glaucoma stages at the diagnosis verification and at the final
examination timepoints, n=237, ±m, e (Q25%; Q75%), 
\r
\t
index
\b
Mild POAG
ƒ\r\f
Moderate
POAG

\r„„
Advanced POG
…\b
Terminal POAG

\f\b
Statistical
significance
, p/H

Total
n=237
-2,7±0,14
-2,69
(-4,00; -1,21)
-7,77
(-9,90; -6,45)
-14,58±0,45
-13,82
(-16,00; -12,84)
-25,17±1,09
-25,08
(-30,00; -21,49)
  \f, ..
\n \f —
  /
no significance, since
different disease stages
serve as inclusion criteria
(-9,68; -2,37)
PSD
3,01±0,14
(1,84; 3,87)
(4,18; 7,36)
7,04
(5,76; 10,22)
6,72±0,93
7,08
(5,11; 8,52)
p0,001
(2,14; 6,06)
\f\f 3.
  \t   \b \n\f,
n=237, ‚±m, ‚e (Q
Table 3.
n=237, ±m, e (Q
ÔÚŸ™–—\t\b\rÙ”“\r
‘ ™蟙ŸŸÅ‘™   ‘Ÿ ™  Å‘—Ÿ™  \t™\r
\r\r\r\r\b\r\r\nˆ
\b\r\f„
›‚…\r\r
\r\n„­›‡\b„
\r\n\r\r\n‚
\r\r\r\f\r\r\r
\r\r„Ì\r
\r\r\r\r\r\r“­›
™\r‚\r\r
\b\r\f\r\r Äæ‡\t
\r\f\r\r\r\f\b
™\r\b‚\n\r\r\r\r
\b\r„‚\b\r\r\r\r\nˆ
‡\n\r\b\r\r\f
\b\r\b\b\b\r\rÌ­Ä\r\r
š›œ­\r\r\r\r\n\r\r
\b\r\b\b
ҁ\nÈÑÓ
Ì\bˆ\n\r\n\r™
\r\r\r\n\n\r\r
\r\n\r\rÌ­Ä
ŠŠÚ€‚\fÛ
\f\f 5.
 \t\r †…ƒ   \f‡ \t€\f \f \f,
n=237, ‚±m, ‚e (Q
Table 5.
Baseline average central cornea thickness (CCT), n=237, ±m, e (Q
\b
Mild POAG
ƒ\r\f
Moderate POAG
 \r„„
Advanced POG
…\b
Terminal POAG

\f\b
Statistical
significance,
p/H

Total
n=237
CCT
542,74±2,55
543,00
(526,00; 562,00)
540,12±5,39
(502,00; 568,00)
530,43±6,97
(503,00; 554,00)
539,14±9,48
(526,00; 557,00)
543,00
(520,00; 562,00)
\f\f 7.
­\f\b  \f \r\f      \b \n\f,
n=237, M±m, M (Q
),  ..
Table 7.
IOP according to glaucoma stage at the final examination timepoint,
n=237, M±m, M (Q
\b
Mild POAG
ƒ\r\f
Moderate POAG
 \r„„
Advanced POG
…\b
Terminal POAG

\f\b
Statistical
significance
, p/H

Total,
n=237
­„…
19,13±0,24
19,00
(17,00; 21,00)
19,22±0,37
19,00
(17,00; 20,00)
19,50
(18,00; 21,50)
20,14±1,52
19,50
(16,00; 22,00)
p=0,557
19,32±0,2
19,00
(17,00; 21,00)
\b 
Mild POAG
ƒ\r\f 
Moderate POAG
 \r„„
Advanced POAG

\f\b
Statistical
significance
, p/U

Total
n=237
­„…
(24,00; 27,00)
29,29±0,59
(26,00; 32,00)
(28,00; 37,00)
0,001
0,001
=-3,583
=-0,574
(24,00; 28,00)
\f\f 6.
­\f\b  \f \r\f      \f
\r\n\f, n=237, M±m, M (Q
),  ..
Table 6.
IOP according to glaucoma stage at the diagnosis verification timepoint,
n=237, M±m, M (Q
\r\r\rП™Ÿ†™Ÿ–ÑÄ\r\r
\b\r™\r\n\rž\n\r
™žÌ­Ä\r\r\r
›\r\r\f\b
\b\b\b„\r\r\f\ržž\f
š›œ­\r\r\r\n\r
\r\n€\n\rž\r\r
\ržž\fš›œ­™\ržž\r
‡\r\r\r\r\n\r\r
\r\r\r\f„\rÌ­Ä\r
\b\r\b\b™\b„
™\r\r“­›\b„\r
\ržž\f\f\r™\r‚
š\r\f\n\r
\r\n\r\r\r\n€\r\f\r„\r\r
\r\r\r\r\b\r\n‚
\b„Ä\r\n\r\r\r\rÇ
ÉÇžÉ\r™
\r\n\r\r\r\r\r
\r‚\b\r\r\r
\r\r\r\r\r\rÇÉ
\r\n\r
Ì…\r\f\r\f\n\r\b\r\b
\r\r\r\r‚
ˆ™‚ˆ\r\r\rÌ­Ä
\r
„‚\b\r„\r\r\r
\r\r\r\r\r\r
\b\b\r\r\r\f\r
\fÊÇž\fÉ\r
Ì­Ä™\r\r\f\r\b\rÌ­Ä™
\r\f\b\r\r
\b\b\n\t\n€
 ˆ\f\rÌ­Ä\b\r
\t™\r\r\f‚Ç\b\fÉ
Ç\b\fɍ\rÌ­Ä\b\r\b\r
„\r\n\rÄ\r\b
Çž\r\rÌ­ÄÉ\b‚
ˆ‚\r
ÜÊÇž\fÉ\rÌ­Ä™
ʪ\f\rÌ­Ä
Ê\b\r\b\r\r
ʪ\f\rÌ­Ä
Ê\b\r\b\r\r
Ê\b\r\r\r\n\r\r\r\r\f
š\r‚\r\r™
\rž\b„\r\r\f\fš›œ­
Çž\r\rÉ\rÌ­Ä\r\r
\r\r“­›\r‚\r\r
\r\r\f\r™\r
\b„\r\r\f™\ržž\f
\r\fš›œ­…\r\b\r\r\r
\ržÌ\r\r\r\b\r\r
\r\r\rÇž\rÉ\rÌ­Ä
\r\n\r\r\r\r\b\r\r\n\r™
\r\rˆ\r\b„\b\r\n\r
\r™\r\r
ž\r\r\r\r\b\r
̍\r\r„\r\r\f™\b\r
\b\r„“­›“\r\b\r\r\r
\b\r™\r\r\r\r\n\n\r\b
\b\r\f\r\r\r\r
\b„\rš›œ­
Ì™\b
\nÑ
‚\r\r™\r\rÌ­Ä\r
\r\r\r\n\r\b„\r
š›œ­\r\r\r\r ¥Ú ™‘‘†™
ÔÚŸ™ †\t\rÞ Þ™Ÿè ™Ÿ Å
†ÅŸ\t\t›…\r™\r\b\n\r
\r\b\r\rÌ­Ä„\b
‚\r\r\f™\r\r
ð„‚Ç\r\b\r\rÉ\rÌ­Ä™
Ç\b\r\rɍ„\r\r\r
\r\r™\r\r\r\r\r\r
ž‚\b\r\n\r\b™\b\r\r
\r\rÌ­Ä\r\r
\r\r\r\r\n\r
ҁ\nËÓ
•
\nË
™Ç\b\f
„É\rÌ­Ä\b\r\r\r
\r ¥Ú ™‘Þ†™ÔÚ™––Ÿ\t\b„\r
\r\r
Þ™‘ ޙ蠙Å –ÅŸ\t\t
š\r\r\r\b„\b\b\r\r
\f\r\f\rÌ­Ä™
\r\r\r\r\r™\r\r\r
„\r\r\n\r\r

\r\r\n\r\n\b\b\r\r™\r\b\r
\rš›œ­\b\rÌ­Ä™
\r‚ˆ„\n‚ˆ
„\b™\r\ržÌ\f
\r
ҁ\nÍÊÓ
\r‚
„‚\r\rÇ\r\r\rÉ\r
Ì­Ä\r ¥é ™  ™ÔÚŸ™†‘\t
:
=0,794, U
=0,261 —  \n  \f\n \t \f \n  \n  \f;
=-1,980 —  \n  \f\n \t \f \n  \f ††\n  \f; p
=-2,883 —  \n  \f\n \t \f \n  \f \n  \f; p
=-1,994 —
 \n  \f\n \t \n  \f ††\n  \f; p
=-2,637 — 
\n  \f\n \t \n  \f \n  \f; p
3,4
=0,215, U
3,4
=-1,241 —  
\n  \f\n \t \f ††\n  \f \n  \f.
Note:
1,2
=0,794, U
1,2
=0,261 — statistical significance of the difference between mild and moderate glaucoma; p
1,3
=0,048, U
1,3
=-1,980 —
=-2,883 — statistical significance of the
advanced glaucoma; p
\b
Mild POAG
ƒ\r\f
Moderate
POAG

\r„„
Advanced POG
…\b
Terminal
POAG

\f\b
Statistical
significance
p/H

Total
n=237
«-
†»
­„…
«Average
weighted»
20,26±0,19
(18,90; 21,50)
(18,70; 22,10)
21,43±0,42
21,10
(19,95; 22,90)
22,11±0,76
(21,00; 24,70)
p=0,007; H=11,982
=0,794; U=0,261
=0,048; U=-1,980
=0,004; U=-2,883
=0,046; U=-1,994
=0,008; U=-2,637
=0,215; U=-1,241
20,5±0,15
(19,00; 22,00)
\f\f 8.
«\f\r\f„ » \f\b  \f \r\f     
\b \n\f, n=237, M±m, M (Q
),  ..
Table 8.
«Average weighted» IOP level according to glaucoma stage at he final examination timepoint,
n=237, M±m, M (Q
ÜÚ
ŠŠÚ€‚\fÛ
\b
Mild POAG
ƒ\r\f
Moderate
POAG

\r„„
Advanced POG
…\b
Terminal POAG

\f\b
Statistical
significance
p/H

Total
n=237
«“\b» 
 ­„…  
\b\f
«Optimal» IOP level
during the follow-up
19,16±0,18
19,30
(18,00; 20,70)
19,29±0,29
19,30
(18,00; 20,90)
19,64±0,4
19,60
(17,90; 21,00)
(18,00; 21,70)
p=0,597
19,30±0,14
19,50
(18,00; 21,00)
\f\f 9.
« \t\b » \f\b  \f \r\f      \b
\n\f, n=237, M±m, M (Q
),  ..
Table 9.
«Optimal» IOP level according to glaucoma stage at the final examination timepoint,
n=237, M±m, M (Q
), mm Hg
\b
Mild POAG
ƒ\r\f
Moderate
POAG

\r„„ 
Advanced POG
…\b
Terminal POAG

\f\b
Statistical
significance
, p/H

Total
n=237
«\f»
­„…  
\b\f
«Intolerable»
IOP level during
follow-up
(22,0; 24,5)
(22; 25)
25,11±0,56
(23; 26,5)
27,07±0,56
27
(26; 28)
p0,001; H=32,175
=0,055; U=-1,921
=0,001; U=-3,415
0,001; U=-4,835
=0,065; U=-1,847
0,001; U=-3,585
=0,016; U=-2,408
23,66±0,19
(22; 25)
\f\f 10.
«ˆ » \f\b  \f \r\f     
\b \n\f, n=237, M±m, M (Q
),  ..
\f\f 10.
«Intolerable» IOP level according to glaucoma stage at the final examination timepoint,
n=237, M±m, M (Q
:
=1,921 —  \n  \f\n \t \f \n  \n  \f;
=0,001, U
=3,415 —  \n  \f\n \t \f \n  \f ††\n  \f;
0,001, U
=-4,835 —  \n  \f\n \t \f \n  \f \n  \f; p
=0,065,
=-1,847 —  \n  \f\n \t \n  \f ††\n  \f; p
0,001;
2,4
=-3,585 —  \n  \f\n \t \n  \f \n  \f; p
3,4
=0,016,
=-2,408 —  \n  \f\n \t \f ††\n  \f \n  \f.
Note:
1,2
=0.055, U
1,2
=1.921 — statistical significance of the difference between mild and moderate glaucoma; p
1,3
=0.001, U
1,3
=3.415 —
0.001, U
=-4.835 – statistical significance of the
advanced glaucoma; p
0,001; U
=0.016,
š\r\r\f\f\b„\r
\r\r\f\r\r\r\r
\f\r\r\r\r\f\r\r\f
\nÍÍ
\b\r\n\r\r\r
\r\b„\r\r
\r\r\r\n\r™\r
\r\r\r\b\r\n‚
\r\r\r™\r
\b\r\b\r\b„Ì­Ä™Ç\r\b\r
ÉÌ­Ä™\rˆ\r\r
\r“­›\r\r\f\b\r\f™
Ç\r\b\rÉÊÌ­Ä™\rˆ
ž\f„\r\r\r\r“­›
\b\r™Ç\b\r\b\rÉÊ
Ì­Ä™\rˆ\f„\r\r
\r\r“­›\n\r\b\r\rÇ\r\rÉ
ҁ\nÍÍÓ
\r\r\b
\nÍÍ
™
\b„\r\r\f\fš›œ­\r
\f„\r\n…˜\rÇ\r
\b\rÉ\ržŸ™†Û‡\r
\b„\r\r\f\ržž\f
\b\r„\b„\r™\b\r‚ˆ…
‚\b‚™\r\r˜\r\b\r
\fž\f\r̭č
–™Û\b„\r\r\f–™–ŸÛÊ
\ržž\fš›œ­‡\r
\rꟃ‚\r\r\r
\b„\r\r\f\fš›œ­™\b\r‚
ˆ\r\f\b\r\r\f\b  ™†Û\t™
\b\b\r\f\ržž\f
š›œ­…\r\r‘™Ÿ‘—™ÞÛ
\r\r\r
\b\b\n\t\n€
¢‘—‘‘—’
š\r\r\n\r\b„\r™
\n\r‚ˆ\r\r\f™\r\b
\rƒ„\r\b\rš\r
\r\rÒÍ™‚ˆ\f
\r\r™\r\nˆ‚„
\r\r\f\r‚™\r\r™
\r‚\r\r\r\b„
™\n\r\r\r\b
\fÌ…\r\f\r
\b\r\f\rÌ­Ä…
\b\r\b…\r\b\r\r
\r\r\r\r\r
\b\r\f™\r\b\r\rÌ­Ä
ÒÍ
ҁ\nÍÏÓ
È\b\r\r\n\r
\b„\r\b\b˜\b\r\r
\r\f\r\fÒÍ\b\r\n‚Å
\r\f\r \rƒËÎ\rÅ\r\f\rƒ\r
ƒŸËÎ\rÅ\r\f\n\rƒŸËÎ\r
Ë\r\r\r™\r\b\r\n‚
\b\rÒÍ\b\r\r‚
ŸÞ™‘Û † \t’\r\r\r\r\n€
‚„™\r\r\r™…\r
‡\r\r † ™‘Û —†\t\t
ÒÍ\r„‚˜\b\r\r
 ‘ ™—Û Ÿ \t\tÒ͏ž
ƒËÎ\r™™–Û Ÿ–\tÒ͏
ž\r\rƒŸ\rƒËÎ\r™–™Û
Þ\tÒ͏ž\r\n\r
ƒŸËÎ\r
ҁ\nÍÏÓ
•\b
\nÍÏ

™\b\rÌ­Ä™Ç\r\r\rÉ
\rÌ­Ä™Çž\r
\rɍ\r\r\r\n\b\b
\b„\r\r\b\r\r
ËÎ\r
¡\b\r\f\r\r\r\r
\r™\r\n\rž\n\rÌ­Ä
\r\r\r™\n\r\b
\nÒÍ™™\r
\b\r\r”\r\n\r™\r
\r\r\b\rÒ͏ž\n\r
ƒŸËÎ\r™\rÌ­Ä
\nŸ–™  Ÿ‘™ Å ™ \t”\r\r™\r
\n‚\b\b\r\f\r„
\r\f\r\fÒÍÇ\r\n\rÉÌ­Ä
\r\b\rŸ™™\b\b\r
„\r\f\r\fÒÍ\n\rƒŸËÎ\rÇ
\r\n\rÉÌ­Ä\b\r\r
\rÌ­Ä\b\r\rÊ\r\r
\r\r\r’\r
\r™\r\r\r\r
† ™‘Û —†\t\r\r\r\r\r
\b\n\r\r\rÌ­Ä™\r\b
‚\b\ržÌ­Ä\n\r\r
™\rƒ„\r\r‚
ˆ‚ž‚\r\rÌ
\r\n™\b\r
š\r\b\r\r™\r
„\r\b‚\b\rž\f\r
Ç\r\n\r\rɍ̭ę\r\r\nÌ­Ä
\r\rÊÇ
ž\rÉÌ­ÄÊ\r\rš
\n„‚\r™\r
\b\r\n‚Çž\rÉ
Ì­Ä\n\r\r\r\rŸ ™‘™\b\b\r„
\r\f\r\fÒÍ\n\rƒŸËÎ\rÇ
ž\rÉÌ­Ä\r\b\r
Ÿ™™\r\r\r™\b\r\r…\r\f
\b\b\b„\r\n
š\r\r\r\b„\b\b
\r\r\r\n\b\r
\r\b\f
\r\r\r\b„\r\r\f
\fš›œ­
ҁ\nÍÉÓ
š\r™\r\b\b\b„\rƒ
\r\f\fš›œ­™\b
\b\b\b„\rš›œ­\n\f™
\n\rž\r\r\b\r\r\n\r
\r\b„\r™\r\r
 
Timepoint
  \f  ­
Diagnosis verification timepoint
  \b \n\f
Final examination timepoint

Stage
\f 
mild stage

moderate stage
\f
†† 
advanced stage
\f 
mild stage

moderate stage
\f
†† 
advanced stage
…
Decompensation
4 (2,17)
16 (38,10)
9 (81,82)
14 (10,37)
9 (15,25)
26 (61,90)
€
Compensation
37 (20,11)
18 (42,86)
2 (18,18)
24 (17,78)
24 (40,68)
12 (35,71)

Supercompensation
143 (77,72)
8 (19,04)
0 (0)
97 (71,85)
26 (44,07)
4 (9,52)
­
Total
\f\f 11.
 \f  \t€    \f  \t \r
 ‰ 1    \b \n\f   \t \f ‰ 2-4, n (%)
Table 11.
IOP compensation rate at the diagnosis verification timepoint after regimen \r1
administration and at the final examination timepoint with regimens \r 2-4, n (%)
ŠŠÚ€‚\fÛ
ˆ\r MD
­\f\b   
\f 
verification
«ˆ»
\r \f 
Intolerable IOP
«\f\r\f„»
\r \f 
Average weighted IOP

\f\b/
Statistical
significance
, p/T
�MD0 ƒ/
(dB/year),
25,81±0,46
(24,00; 27,00)
(21,00; 24,50)
20,01±0,28
(18,90; 21,40)
0,001; T=5,506
0,001; T=7,002
0,001; T=7,195
-��1MD0 ƒ/
(dB/year),
(24,00; 28,00)
(22,00; 25,00)
20,39±0,19
(19,10; 21,65)
0,001; T=7,273
0,001; T=9,370
0,001; T=9,427
-2›MD›-1 ƒ/
(dB/year),
27±1,01
(24,00; 29,50)
(23,00; 27,00)
(18,65; 22,3)
=0,015; T=2,247
0,001; T=4,600
0,001; T=4,201
�MD-2 ƒ/
(dB/year),
27,68±0,67
(25,00; 30,00)
26,92±0,74
27,00
(25,50; 30,00)
(21,5; 24,7)
=0,670; T=0,426
0,001; T=3,783
0,001; T=3,724


Statistical
significance
p/U
=0,219; U
=-1,229
=0,393; U
=0,010; U
=-2,582
=0,869; U
=-0,165
=0,057; U
=-1,905
=0,218; U
=-1,233
=0,069; U
=-1,818
=0,003; U
=-2,990
0,001; U
=-4,572
=0,027; U
=-2,208
0,001; U
=0,023; U
=-2,273
=0,311; U
=-1,012
=0,341; U
0,001; U
=-4,281
=0,626; U
=-0,487
0,001; U
=0,003; U
=-2,971
­
Total
n=237
(24,00; 28,00)
23,66±0,19
(22,00; 25,00)
20,5±0,15
(19,00; 22,00)
0,001; T=9,174
0,001; T=13,096
0,001; T=13,110
\f\f 12.
 \t\r \t (MD)     \f
, \n\r   \r\n\f, n=237, ‚±m, ‚e (Q25%; Q75%),  ../
Table 12.
not regarding the disease stage, n=237, ±m, e (Q25%; Q75%), mm Hg/dB
\rÇž\r\rÌ­ÄÉ\nŸ™ Ÿ™—Å
Ÿ™\tš\r\b\r\r‚
\r\r\r™\r\rÇž
\r\rÌ­ÄÉ\bŸ™ Ê\r\r™
\r\r\f\b\r\r\n\r\r\b\r
\rš›œ­\r\f™\b\r
\n\r™\n\n\r
\b\r\r„\r\b\r„
\bž\r
›\nˆ\n\r\b\r\r
\fÇ\r\r\rÉ\rÌ­Ä\b„
\r\n\r\b\r‚ˆ\f\r\r\f˜Ÿ†™  
Ÿ—™  Å ™  \t\r\fš›œ­Ÿ†™  
Ÿ‘™‘ Å ™  \t\b\b\b„\r™\n
\f™\r\r\r\f\r\r™
\r\rˆ‚ˆ„™\b\n\r
\b„\r\r\f„
\b‚\r\r\r\f\r
\r\r\r\r\r™
\r\b\b\r\b\r\f
\n\r\r\r
\n‚„\r\r
•\r\n\r\r\r\rƒ
\r\r\r„\r\r\r\r\r\r
\n\r\b\r\r\b\r\b\r\bŸ †
\r \rƒ\n— ž\t
 Ë™•™•™È\r\r™“\r
™œ\n\t‘„\rÌ\r\f
\n\r\b\r\b\r\b\r
\f™\b\r\b„\r
\b\r\f\r\r\r\r\f\r™
\r\r\r\r
\b\r\n\r™\r
ž\f‚ˆ\f\b\n
\rƒ\r\b\r„\r\b
\r\b\r\r\n\r\r
\f\r\b„\r\r\r
\r\r ™\n
\b\b\t\r—™   ‘Þ™‘Å—–™‘\t\r™
\r\r\r\r\n\rÊ—Þ™  
—™— Å†™† \t”\r\n\r™\n\r
\r\r\r\r\n\r\b„
\r\r\n\r\b\r\b\r
\r™  ™† Å‘™– \t\r
Ë\r\r\r
\f\r\r\r\r\r\r
\r\n\r\b„\r
\r˜\b„\r\f\fš›œ­
\n\r\r\n\r\f\r\r
\r\r\r\r\r\n\r™
\n\r\b\r\n\r
æ\b\r\n‚™  ™† Å‘™– \t\r\b„
\r\r\f\f\ržŸ—™—Û™
…\r\r\r\r\r\n\r
\r\f\ržž\f Ÿ™–— ™†Û
\r\r\r\tÇ\b\rÉ\b\b\b„\r
\r\f\f\r \r\t
\b\b\n\t\n€
ˆ\r MD
­\f\b   
\f

verification
«ˆ»
\r \f 
Intolerable IOP
«\f\r\f„»
\r \f 
Average weighted IOP

\f\b
Statistical
significance
p/T
�MD0 ƒ/
(dB/year),
(24,00; 26,00)
(21,00; 25,00)
(18,70; 22,20)
0,001; T=4,572
0,001; T=6,348
0,001; T=6,586
-1MDœ0 ƒ/
(dB/year),
(24,00; 28,00)
(22,00; 24,50)
(19,00; 21,70)
0,001; T=6,003
0,001; T=8,292
0,001; T=8,353
-2MDœ-1 ƒ/
(dB/year),
(23,00; 26,00)
(22,00; 26,00)
(18,60; 22,20)
=0,535; T=0,621
0,001; T=3,574
=0,001; T=3,266
�MD-2 ƒ/
(dB/year),
26,46±0,57
27,00
(25,00; 28,00)
27,77±0,8
27,00
(26,00; 30,00)
(21,60; 24,40)
=0,026; T=2,223
=0,002; T=3,110
=0,001; T=3,180


Statistical
significance
p/U
=0,143; U
=-1,465
=0,640; U
=0,467
=0,021; U
=-2,317
=0,216; U
=1,237
=0,219; U
=-1,230
=0,052; U
=-1,939
=0,329; U
=-0,976
=0,061; U
=-1,870
0,001; U
=0,122; U
=-1,546
0,001; U
=-4,513
=0,005; U
=-2,835
=0,492; U
=0,970; U
=-0,037
0,001; U
=-3,609
=0,661; U
=0,438
0,001; U
=-3,745
=0,006; U
=-2,763
­
Total
(24,00; 27,00)
(22,00; 25,00)
20,47±0,18
(18,85; 22,20)
0,001; T=6,800
0,001; T=11,425
0,001; T=11,556
\f\f 13.
 \t\r \t (MD)     \f
  \t€\f  \b  \r\n\f, n=184, ‚±m, ‚e (Q
),  ../
Table 13.
in patients with mild glaucoma, n=184, ±m, e (Q
), mm Hg/dB
Ì\r\f\n\r\n\r
\r\r\r‚ˆ™‚ˆ
\r\r\r\r\r
\r˜Çž\rÌ­ÄÉ™Ç\r\b\r
Ì­ÄÉ™Ç\r\rÌ­ÄÉœ\r\r™\rž
\b„\r\r\f\fš›œ­
Çž\r\rÌ­ÄÉ\r\r\r
\r“­›\r‚\r\r\r\r\f
\r™\r\b„\r\b\r
š›œ­Çž
\r\rÌ­ÄÉ\n\rž\f\r\r\r
\b\r\rÇ\r\n\r\rÉ\r
̭㙑̍\r
\r\r\b\r\r\r\r\rÇž
\rÌ­ÄÉ\r\n\r\r\b\r\r
\b\r\n\r
š\b\r\f\r\f\b
\r\r™\r\b\r\r\r™
\r\r„\r\f
ÒÍ\n\rƒŸËÎ\r™\r\r\r\r\r
‚Çž\r\rÌ­ÄÉŸ˜Ÿ™  
Ÿ™‘ ÅŸ™† \t\b\b\b„\r\n
\f\b\r\f\r\r\r\r\f\r™
Ÿ™  Ÿ™— ÅŸ™ \tʍ\b„\r\r\f
\f\rš\r\b\r\r
‚\r\r\r™\r\rÇ
ž\r\rÌ­ÄÉ\bŸÊ\r
\r™\r\r\f\b\r\r\n\r\r\b\r
\rš›œ­\r\f™
\b\r\n\r™\n\n\r
\b\r\r„\r\b\r„
\bž\r
̍\r\b\r\r\fǃ
\r\n\r\rÌ­ÄÉ\b„\r\n\r\b\r‚
ˆ\f\r\r\fÊŸ†™   Ÿ—™  Å ™  \t
\r\fŸ†™   Ÿ‘™‘ Å ™  \tʍ\b\b
\b„\r™\n\f™\r\r™
\r\rˆ‚ˆ„™\b\n\r
\b„š›œ­„
\b‚\r\r\r\f\r\r\r
\r\rš›œ­™\r
\b\b\r\b\r\f
\n\r\r\r
”\r\n\r™\r\r\r
\r\n\b\r\r\r„ˆ
‚ˆ\r„\f™‚
ˆ\r\r\b„\b\n\rƒ\r\r\f
\n\r\r\r\f™\r\r
\n\r™\r\r\r\r\r\r
\r\b\r\r\r\r
\r‚ˆ™‚ˆ\r\r
\r\r\r
ŠŠÚ€‚\fÛ

á\r\rá¡™ÌÈÌÌ\r\rˆ
\n\t
Ÿ  —ÅŸ˜ƒ—
•\r\r¡Ì™­\r\nñ™ã\r­Ì
\n\t
Ÿ  ‘ÅŸ˜†ƒÞ
\nၙᡙáä’’\b\r\r
\r­\r˜\r™„™\r\r\n
\f\r\r\f\r„™ƒ\fÈ™Ÿ  —ÅŸ †ƒŸŸ

¸¦¯²‹‹Óµ©²³²¯««©²¥§¨©¯²¨«·©¨¦¨¬¯§¨¯³°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  Å ˜†Ÿ—ƒ†
‘
‰¬²¯«¨‹Ï™Žª¦°®¨¯²ÏŽ™Ó¯ªÀ¯¬«Ôϯ¨§µò¯´©³¯²ª¯ƒ¶§«¯³
¬¯´©¯·°±¥¬°¹²°«¨©ª±§ª¨°¬«±°¬¹µ§®ª°¤§¨°®«´©«®§µ±©¯µ³¥¬°¹¬¯««©°²
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ ÅŸ ˜‘Ÿƒ‘Þ
—
½µ°¶§µº²©¨©§¨©´¯±°¬¨¦¯‰µ©¤©²§¨©°²°±ô°©³§¶µ¯Óµ©²³²¯««˜§ª¨©°²
¥µ§²Ÿ  —ƒŸ åÔ»Ô¯§³ï®§¬¨¯¬«™½¯²¯´§™Ž·©¨Á¯¬µ§²³™ƒÏ®µ£
†
½¬°¶¶¯¯Í‰™Ô°¯«Ã帵©²©ª§µ¯¥©³¯¤©°µ°¹£˜¥¬©²ª©¥µ¯«™¤¯¨¦°³«™
§²³§¥¥µ©ª§¨©°²«±°¬ªµ©²©ª§µ¬¯«¯§¬ª¦¢°²³°²™Ï°²¯«§²³Ó§¬¨µ¯¨¨
‹®¶µ™Ÿ  Þ ƒ —¥¥
Ô¯©¾µÃ™Ó¯²¹¨««°²Ó™Ô£¤§²¢™¢¯«À¯Ò¸‰§¬µ£Ò§²©±¯«¨½µ§®ª°¤§
¼¬©§µ½¬°®¥¿§¨®¬§µ¦©«¨°¬£°±°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  ÞÅ—˜ŸŸ†ƒŸŸ†—
Þ
ߧ¨ÁÏ™¼©¯µ«ª¦ÏÒ™í®©¹µ¯£Ô﨧µ¤§¨¯³«®¥¬§¨¦¬¯«¦°µ³
«ª¬¯¯²©²¹±°¬¹µ§®ª°¤§˜¨¦¯Ó§µ¨©¤°¬¯‰£¯Ž¨®³£
»œ§š½¥ÁÄ™¥™¤®¸¦®
¡²½°¼²
ÞÞŐ Ÿ\t˜Ÿ†ƒŸ††
 
ß·°²ÝÔ™Ö©²¹¯¬¨Ïԙ߮¯¦²ÒÔ™õ·§¬³å¢‹¬©¤§¬£°¥¯²ƒ
§²¹µ¯¹µ§®ª°¤§
¨Åœ£®×ºš«
Ÿ  ÞÅ—  \t˜ƒŸ

í®©¹µ¯£ÔÙ󳩪À«‰Ò™½¬¯¯²åŒ»¥¨©ª²¯¬´¯³§¤§¹¯©²¦®¤§²
¹µ§®ª°¤§˜ºººí®§²¨©¨§¨©´¯ª°¬¬¯µ§¨©°²°±²¯¬´¯±©¶¯¬µ°««§²³´©«®§µ
±©¯µ³³¯±¯ª¨©²¹µ§®ª°¤§™©«ª¦¯¤©ª²¯®¬°¥§¨¦£™¥§¥©µµ¯³¯¤§™§²³¨°Š©ª
²¯®¬°¥§¨¦£
ª›¼™ÁÄ™¥™¤®¸¦®
Þ–ŸÅ   \t˜‘ƒ—
Ÿ
í®©¹µ¯£ÔÙͮ²À¯µ¶¯¬¹¯¬½Œ™½¬¯¯²åŒŒ¯¨©²§µ¹§²¹µ©°²ª¯µµ
§¨¬°¥¦£ª°¬¬¯µ§¨¯³·©¨¦§®¨°¤§¨¯³¥¯¬©¤¯¨¬£©²¦®¤§²¯£¯«·©¨¦
¹µ§®ª°¤§
ª¸×ÁÄ™¥™¤®¸¦®
Þ–ÞÅ † ‘\t˜‘ƒ—

í®©¹µ¯£ÔÙӬ°¤§²Ã¼¼¦¯²®¤¶¯¬°±¥¯°¥µ¯·©¨¦¹µ§®ª°¤§
·°¬µ³·©³¯©²Ÿ  §²³Ÿ Ÿ 
¢›×ÁÄ™¥™¤®¸¦®
Ÿ  —ÅÞ ˜Ÿ—ŸƒŸ—†

á\r\rá¡™¡\rñ™áÌš‡„\r\r\r\r
\r\b\r\rȘ­’›”¡“ƒÈŸ ‘Ő‘—
‘
á\r\rá¡™•\r\r¡Ì›\rƒ…\b\r\r
\r‡­­“
\r\r„\r\r\r\r\r\r\r\b\r\r\r
\t
Œˆ\n€\b\tƒ\n­\n
Ÿ Å˜Þ†ƒ  
—
á\r\rá¡™•\r\r¡Ì›\rƒ…\b\r\r
\r‡­­“
\r\r„\r\r\r\r\r\r\r\b\r\r\r
Ÿ\t
Œˆ\n€\b\tƒ\n­\n
Ÿ ŸÅ˜ÞƒŸŸ
†
¡“Ì™¡\r¡™Ë\f¡Æ\r™
\b\r\r\b\r\r\b\r
\r\r„\r\r\r\r“\r\f\r\r\r\r\r
\r\nˆ
\f\t—\n€\b\tŠ\n\f\n­\b
Ÿ ŸÅŸ –\t˜‘†ƒ—Þ
–
¡“Ì™¡\r¡™Ë\f¡•\r\r
\r„\r\r\r…\r\r\n…\r
Ì\n­‚\n\n\t
Ÿ ÅŸ Ÿ\t˜‘ƒ— 
Þ
¡“Ì™¡\r¡™Ë\f¡\b
\r\r\r\r„\r\r\r
\rž\f\b\r\f\r\r\r\r\f\r\r\f\r
\r\f
‡ƒ\n­\n€\b\t\f\b
Ÿ Å† \t˜ÞƒŸ†
¡“Ì™¡\r¡™Ë‡¡š\r\r\r
\b\r\r\r\r\r\n\r\r\b„
\r\b\r\f\r\r\r\r\f\r
Ì\n­‚\n\n\t
Ÿ Å Ÿ\t˜— ƒ—Þ
Ÿ
¡\nžÄ™¡“Ì™¡\r¡È\r\r„
\r\r\r\b\r‚\b\r\f\r\r\r
\b„\r\b\r\b\r\f\r\r\r
\r\f\r\r\b\r\r\r\r
‡ƒ\n­\n€
\b\t\f\b
Ÿ ‘Å– \t˜ƒ— 
•\r\r¡Ì™¡\nžÄ™¡“Ì“
\r\r\rž…\r\r\r\b\b
\r\f\b\r\r\f\b\b„\r\b\r
\b\r\f\r\r\r\r\f\r \r\r„
\r\r\r\t
\b\b‚\b\t‚ƒ\n­\n€\b\t‚\n
Ÿ ‘Å– \t˜ ƒŸŸ
  \r 
References

‰¹°¬°´‰Ã™§«©²§Òº²¨¬§°ª®µ§¬¥¬¯««®¬¯§²³¨¦©ªÀ²¯««°±¨¦¯
ª°¬²¯§
Ÿ  —ÅŸ˜ƒ—
ß®¬°£¯³°´Ã™½°µ®¶¯´ŽÝ®™Ž¦§±¬§²°´½Â
Ÿ  ‘ÅŸ˜†ƒÞ

¢©¯¶¤§²‰Ž™¸¦®¤§¯´§‰Ã™ݯµÀ©²§ݧ‰‰¥©³¯¤©°µ°¹©ª§µ±¯§¨®¬¯«
°±¹µ§®ª°¤§½µ§®ª°¤§˜¨¦¯°¬£™¨¬¯²³«™¨¯ª¦²°µ°¹£쨩ªµ¯«ª°µµ¯ª¨©°²
°±¨¦¯¨¦©²¨¯¬²§¨©°²§µª°²±¯¬¯²ª¯Ò°«ª°·™Ÿ  —Ÿ †ƒŸŸ¥¥

¸¦¯²‹‹Óµ©²³²¯««©²¥§¨©¯²¨«·©¨¦¨¬¯§¨¯³°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  Å ˜†Ÿ—ƒ†
‘
‰¬²¯«¨‹Ï™Žª¦°®¨¯²ÏŽ™Ó¯ªÀ¯¬«Ôϯ¨§µò¯´©³¯²ª¯ƒ¶§«¯³
¬¯´©¯·°±¥¬°¹²°«¨©ª±§ª¨°¬«±°¬¹µ§®ª°¤§¨°®«´©«®§µ±©¯µ³¥¬°¹¬¯««©°²
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ ÅŸ ˜‘Ÿƒ‘Þ
—
½µ°¶§µº²©¨©§¨©´¯±°¬¨¦¯‰µ©¤©²§¨©°²°±ô°©³§¶µ¯Óµ©²³²¯««˜§ª¨©°²
¥µ§²Ÿ  —ƒŸ åÔ»Ô¯§³ï®§¬¨¯¬«™½¯²¯´§™Ž·©¨Á¯¬µ§²³™ƒÏ®µ£
†
½¬°¶¶¯¯Í‰™Ô°¯«Ã帵©²©ª§µ¯¥©³¯¤©°µ°¹£˜¥¬©²ª©¥µ¯«™¤¯¨¦
°³«™§²³§¥¥µ©ª§¨©°²«±°¬ªµ©²©ª§µ¬¯«¯§¬ª¦¢°²³°²™Ï°²¯«§²³Ó§¬¨µ¯¨¨
‹®¶µ™Ÿ  Þ ƒ —¥¥
Ô¯©¾µÃ™Ó¯²¹¨««°²Ó™Ô£¤§²¢™¢¯«À¯Ò¸‰§¬µ£Ò§²©±¯«¨½µ§®ª°¤§
¼¬©§µ½¬°®¥¿§¨®¬§µ¦©«¨°¬£°±°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  ÞÅ—˜ŸŸ†ƒŸŸ†—
Þ
ߧ¨ÁÏ™¼©¯µ«ª¦ÏÒ™í®©¹µ¯£Ô﨧µ¤§¨¯³«®¥¬§¨¦¬¯«¦°µ³
«ª¬¯¯²©²¹±°¬¹µ§®ª°¤§˜¨¦¯Ó§µ¨©¤°¬¯‰£¯Ž¨®³£
»œ§š½¥ÁÄ™¥™¤®¸¦®
¡²½°¼²
ÞÞŐ Ÿ\t˜Ÿ†ƒŸ††
 
ß·°²ÝÔ™Ö©²¹¯¬¨Ïԙ߮¯¦²ÒÔ™õ·§¬³å¢‹¬©¤§¬£°¥¯²ƒ
§²¹µ¯¹µ§®ª°¤§
¨Åœ£®×ºš«
Ÿ  ÞÅ—  \t˜ƒŸ

í®©¹µ¯£ÔÙ󳩪À«‰Ò™½¬¯¯²åŒ»¥¨©ª²¯¬´¯³§¤§¹¯©²¦®¤§²
¹µ§®ª°¤§˜ºººí®§²¨©¨§¨©´¯ª°¬¬¯µ§¨©°²°±²¯¬´¯±©¶¯¬µ°««§²³´©«®§µ
±©¯µ³³¯±¯ª¨©²¹µ§®ª°¤§™©«ª¦¯¤©ª²¯®¬°¥§¨¦£™¥§¥©µµ¯³¯¤§™§²³¨°Š©ª
²¯®¬°¥§¨¦£
ª›¼™ÁÄ™¥™¤®¸¦®
Þ–ŸÅ   \t˜‘ƒ—
Ÿ
í®©¹µ¯£ÔÙͮ²À¯µ¶¯¬¹¯¬½Œ™½¬¯¯²åŒŒ¯¨©²§µ¹§²¹µ©°²ª¯µµ
§¨¬°¥¦£ª°¬¬¯µ§¨¯³·©¨¦§®¨°¤§¨¯³¥¯¬©¤¯¨¬£©²¦®¤§²¯£¯«·©¨¦
¹µ§®ª°¤§
ª¸×ÁÄ™¥™¤®¸¦®
Þ–ÞÅ † ‘\t˜‘ƒ—

í®©¹µ¯£ÔÙӬ°¤§²Ã¼¼¦¯²®¤¶¯¬°±¥¯°¥µ¯·©¨¦¹µ§®ª°¤§
·°¬µ³·©³¯©²Ÿ  §²³Ÿ Ÿ 
¢›×ÁÄ™¥™¤®¸¦®
Ÿ  —ÅÞ ˜Ÿ—ŸƒŸ—†

‰¹°¬°´‰Ã™먧¦°´Ý®Ž™‰¬©ª¦¯´Â‹¿§¨«©°²§µ×²°¯¬®À°´°³«¨´°¥°
¹µ§®À°¤¯нµ§®ª°¤§˜²§¨©°²§µ¹®©³¯µ©²¯«ÑÒ°«ª°·™½‰»¼ÃŒƒÒ¯³©§
‹®¶µ™Ÿ ‘Ő‘—¥
‘
‰¹°¬°´‰Ã™ß®¬°£¯³°´Ã¸µ©²©ª§µ§²³¯¥©³¯¤©°µ°¹©ª§µª¦§¬§ªƒ
¨¯¬©«¨©ª«°±¹µ§®ª°¤§©²¸ºŽ§²³½¯°¬¹©§Œ¯«®µ¨«°±¤®µ¨©ª¯²¨¯¬
°¥¯²¯³¬¯¨¬°«¥¯ª¨©´¯¨¬©§µ ¥§¬¨\t
¬º×˜®²œ²¼¤®ÁÄ™¥™¤®¸¦®¦£ž
Ÿ Å˜Þ†ƒ  
—
‰¹°¬°´‰Ã™ß®¬°£¯³°´Ã¸µ©²©ª§µ§²³¯¥©³¯¤©°µ°¹©ª§µª¦§¬§ªƒ
¨¯¬©«¨©ª«°±¹µ§®ª°¤§©²¸ºŽ§²³½¯°¬¹©§Œ¯«®µ¨«°±¤®µ¨©ª¯²¨¯¬
°¥¯²¯³¬¯¨¬°«¥¯ª¨©´¯¨¬©§µ ¥§¬¨Ÿ\t
¬º×˜®²œ²¼¤®ÁÄ™¥™¤®¸¦®¦£ž
Ÿ ŸÅ˜ÞƒŸŸ
†
ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ™Ó§«©²«À£ÃŽ¯¨§µŒ©«À±§ª¨°¬«™¥§¨¦°
¹¯²«³¯´¯µ°¥¤¯²¨§²³¥¬°¹¬¯««©°²°±¨¦¯¬¯«®µ¨«°±§¤®µ¨©ª¯²¨¯¬
«¨®³£°±Œ®««©§²¹µ§®ª°¤§«°ª©¯¨£
ºš«²¼¤®¤œ«·²¦®¦£²¼¤®Ä›¦·®š¸½¦¾
®²¾š
Ÿ ŸÅŸ –\t˜‘†ƒ—Þ
–
ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ™Ó§«©²«À£ÃŽ¯¨§µ¸µ©²©ª§µ¤®µ¨©ª¯²¨¯¬
«¨®³£°±¨¬§¶¯ª®µ¯ª¨°¤£¯±±©ª§ª£
¨¤¥½²¦œ¤®Çœž²´™±›œ¤®£®¤±Ÿ¦¸¤
Ÿ ÅŸ Ÿ\t˜‘ƒ‘‘
Þ
ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ™Ó§«©²«À£ÃŽ¯¨§µ¼¦¯³¯¹¬¯¯°±¤®¨®
§µ©²±µ®¯²ª¯§²³¨¦¯¬¯µ§¨©°²«¦©¥¶¯¨·¯¯²¤°¬¥¦°µ°¹©ª§µ§²³±®²ª
¨©°²§µª¦§¬§ª¨¯¬©«¨©ª«°±¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§§²³¤§ª®µ§¬
³¯¹¯²¯¬§¨©°²
ÁÄ™¥™¤®¸¦®¦£²¼§š«¦¸¦½¥²
Ÿ Å† \t˜ÞƒŸ†
Ÿ 
ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ™Ó§À£²©²§¿Ã¯¨§µ‹¬¯³©ª¨©°²°±
¨¦¯³©«¯§«¯³®¬§¨©°²§²³¨¦¯§¹¯°±¥§¨©¯²¨«·©¨¦³©±±¯¬¯²¨«¨§¹¯«
°±¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
¨¤¥½²¦œ¤®Çœž²´™±›œ¤®£®¤±Ÿ¦¸¤
Ÿ Å Ÿ\t˜— ƒ—Þ
Ÿ
ö£«¦¯´§¢Í™ô³¯¯´ŒÂ™õ¯Š§²³¬°´ÃŽ¯¨§µÒ®µ¨©ª¯²¨¯¬«¨®³£
°±©²¨¬§°ª®µ§¬¥¬¯««®¬¯µ¯´¯µ©²¥§¨©¯²¨«·©¨¦¤°³¯¬§¨¯§²³§³´§²ª¯³
¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§°²¨¬¯§¨¤¯²¨
ÁÄ™¥™¤®¸¦®¦£²¼§š«¦
¸¦½¥²
Ÿ ‘Å– \t˜ƒ— 
ŸŸ
ß®¬°¯³°´Ã™ö£«¦¯´§¢Í™ô³¯¯´ŒÂ¯¨§µ¼¦¯¬¯«®µ¨«
°±¨¦¯«¨®³£§²³ª°«¨¯±±¯ª¨©´¯²¯««¬§¨©°°±ª°«¨«©²¨¦¯§¥¥µ©ª§¨©°²
°±µ°ª§µ¦£¥°¨¯²«©´¯¨¦¯¬§¥£©²¥§¨©¯²¨«·©¨¦§³´§²ª¯³¥¬©¤§¬£°¥¯²ƒ
§²¹µ¯¹µ§®ª°¤§ ¤®µ¨©ª¯²¨¯¬«¨®³£\t
¬±½½²¤œÁÄ™¥™¤®¸¦®¦£²¼¤®×
Ÿ ‘Å– \t˜ ƒŸŸ
\b\b\n\t\n€
Ÿ
¡\nžÄ™¡“Ì™¡\r¡›\b
\f„\r\r\r\b„\r
\r\f\f\b\r\f\r\r\r\r\f\r
\r\r\r\f„
Œˆ\n€\b\t
ƒ\n­\n
Ÿ ‘Å— \t˜ƒŸ
Ÿ
•\r\r¡Ì™¡“Ì™¡\r¡š
\r\r\r\r˜\r\r\b„\b\r\f
\r\n\r\r\b\b\r
\f\t—
\n€\b\tŠ\n\f\n­\b
Ÿ ÅŸ Ÿ\t˜†ƒ–
Ÿ‘
¡“Ì™¡\r¡™Ë‡¡È\r
\r\r\r\b\r\f\r\r\r\r\f\r
ˆ\n€\b\t\fÌ
Ÿ ÅÞŸ Ÿ\t˜—ƒ†Ÿ
¡“Ì™¡\r¡™Ë\f¡È\r\r„\r
\r\r\b\r\r\b‚\rƒ„\r\r\r
\r\r\r\b\r\r\r
\r\r\r\f\r\f„
\r„\r\f\b\r\r
‡ƒ\n­\n\b€‹Š
Ÿ Ő˜‘ƒŸ‘
٠
•\r\r¡Ì™¡“Ì™¡\r¡š\b\r
\f\r\b„\r\b\r\n\r\b\r
\n\rƒ\b\r\b„\f\b\b\r\f
\r
‡ƒ\n­\n\b€‹Š
Ÿ Å ŸŸ\t˜— ƒ†
Ÿ–
¡\nžÄ™¡\r¡™¡\bÈœ›\b
„\n\rƒ\r\r\r\b\r„\b„\r\b\r\f
\r\r\r\r\f\r\r\f
Ì\n­‚\n\n\t
Ÿ —Å‘ Ÿ\t˜Þƒ‘
½°¬³°²Ò»™½§°Ö™Ó¯©«¯¬Ï﨧µ¼¦¯ ƒ£¯§¬©²ª©³¯²ª¯°±¹µ§®
ª°¤§§¤°²¹¥§¨©¯²¨«·©¨¦¨¬¯§¨¯³§²³®²¨¬¯§¨¯³°ª®µ§¬¦£¥¯¬¨¯²«©°²
ª›¼™ÁÄ™¥™¤®¸¦®
Ÿ ÅŸÞ Ÿ\t˜— ƒ—
 
Ó¬§²³¨Ï͙ӯ©«¯¬ÏÙ½°¬³°²Ò»¯¨§µ¸¯²¨¬§µª°¬²¯§µ¨¦©ªÀ²¯««
§²³¤¯§«®¬¯³º»‹¬¯«¥°²«¯¨°¨°¥©ª§µ°ª®µ§¬¦£¥°¨¯²«©´¯¤¯³©ª§¨©°²
©²¨¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£
ª¸×ÁÄ™¥™¤®¸¦®
Ÿ  Å– ‘\t˜††ƒ†ŸŸ

¸°µ¯¤§²Ã¢™½°¬³°²Ò»™Ó¯©«¯¬Ï﨧µÓ§«¯µ©²¯¬©«À±§ª¨°¬«
±°¬¨¦¯³¯´¯µ°¥¤¯²¨°±¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§©²¨¦¯»ª®µ§¬
Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£
ª¸×ÁÄ™¥™¤®¸¦®
Ÿ  Å– \t˜
—–ƒ—–‘
Ÿ
Ó¬§²³¨Ï͙ӯ©«¯¬ÏÙߧ««Ò﨧µ¸¯²¨¬§µª°¬²¯§µ¨¦©ªÀ²¯««
©²¨¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£ »Ô¼Ž\t
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  Å –  \t˜††Þƒ†––
¡Ì‡™Ë̍\rˆ\r\r„\r
\r\r\b\r\r\b\b\r\f\r\r\r
\r\f\r
Œˆ\n€\b\tƒ\n­\n
Ÿ  –Ő˜ 

½°¬³°²Ò»™Ó¯©«¯¬ÏÙӬ§²³¨Ïͯ¨§µ¼¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²
¼¬¯§¨¤¯²¨Ž¨®³£˜¶§«¯µ©²¯±§ª¨°¬«¨¦§¨¥¬¯³©ª¨¨¦¯°²«¯¨°±¥¬©¤§¬£
°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ª›¼™ÁÄ™¥™¤®¸¦®
Ÿ  ŸÅŸ  —\t˜†ƒ†Ÿ 
Ÿ
ö£«¦¯´§¢Í™ô³¯¯´ŒÂ™õ¯À«§²³¬°´ÃŽ¯¨§µ»¥¨©¤®¤¥¯¬
±°¬¤§²ª¯°±¨¦¯®¥¥¯¬µ©¤©¨°±º»‹©²¥§¨©¯²¨«·©¨¦§³´§²ª¯³«¨§¹¯
¥¬©¤§¬£°¥¯²§²¹µ¯¹µ§®ª°¤§©²¨¯¬¤«°±¯´©³¯²ª¯ƒ¶§«¯³¤¯³©ª©²¯
¬º×˜®²œ²¼¤®ÁÄ™¥™¤®¸¦®¦£ž
Ÿ ‘Å— \t˜ƒŸ
Ÿ
ß®¬°¯³°´Ã™ô³¯¯´ŒÂ™õ¯À«§²³¬°´ÃŽ¯¨§µ‹¬©¤§¬£°¥¯²ƒ
§²¹µ¯¹µ§®ª°¤§˜¥§¨©¯²¨×«§¹¯§²³³©«¯§«¯³®¬§¨©°²§¨·¦©ª¦¶µ©²³²¯««
¤§£°ªª®¬
ºš«²¼¤®¤œ«·²¦®¦£²¼¤®Ä›¦·®š¸½¦¾®²¾š
Ÿ ÅŸ Ÿ\t˜†ƒ–
ô³¯¯´ŒÂ™õ¯À«§²³¬°´ÃŽ™Ó§À®²©²§¿Ã¯¨§µÒ°³¯µ°±¥¬©¤§¬£
°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§°®¨ª°¤¯«
˜®²œ²¼¤®¸š«²¼²œš
Ÿ ÅÞŸ Ÿ\t˜
—ƒ†Ÿ
Ÿ—
ô³¯¯´ŒÂ™õ¯À«§²³¬°´ÃŽ™Ó§«©²«À©©ÃŽ¯¨§µÒ®µ¨©ª¯²¨¬¯
«¨®³£°±¤°¬¥¦°±®²ª¨©°²§µ«¨§¨®«°±´©«®§µ§²§µ£Á¯¬©²«©¤®µ¨§²¯°®«
¥¬¯«¯²ª¯©²¯£¯¹µ§®ª°¤§§²³§¹¯ƒ¬¯µ§¨¯³¤§ª®µ§¬³¯¹¯²¯¬§¨©°²
·©¨¦³¯¨¯¬¤©²§¨©°²°±ª°¬¬¯µ§¨©°²«§²³ª°²²¯ª¨©°²«
ÁÄ™¥™¤®¸¦®¦£ž
Ť½¥š›œű›¦Äš
Ÿ Ő˜‘ƒŸ‘
٠
ß®¬°¯³°´Ã™ô³¯¯´ŒÂ™õ¯À«§²³¬°´ÃŽ¯¨§µ¼¦¯¯«¨©¤§¨¯³
§¹¯°±¨¦¯¥§¨©¯²¨«§²³¨¦¯¥¯¬©°³°±¨¦¯³©«¯§«¯±°¬©²¨¯²«©´¯¨¬¯§¨
¤¯²¨©²¥¬©¤§¬£¹µ§®ª°¤§
ÁÄ™¥™¤®¸¦®¦£žŤ½¥š›œű›¦Äš
Ÿ Å
 ŸŸ\t˜— ƒ†
Ÿ–
ö£«¦¯´§¢Í™õ¯À«§²³¬°´ÃŽ™짥©¯´ÒÕ»¥¨©¤©Á§¨©°²°±³©§¹
²°«©«§²³¨¬¯§¨¤¯²¨°¥¨©°²«©²¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§¥§¨©¯²¨«
¨¤¥½²¦œ¤®Çœž²´™±›œ¤®£®¤±Ÿ¦¸¤
Ÿ —Å‘ Ÿ\t˜Þƒ‘
ŸÞ
½°¬³°²Ò»™½§°Ö™Ó¯©«¯¬Ï﨧µ¼¦¯ ƒ£¯§¬©²ª©³¯²ª¯°±¹µ§®
ª°¤§§¤°²¹¥§¨©¯²¨«·©¨¦¨¬¯§¨¯³§²³®²¨¬¯§¨¯³°ª®µ§¬¦£¥¯¬¨¯²«©°²
ª›¼™ÁÄ™¥™¤®¸¦®
Ÿ ÅŸÞ Ÿ\t˜— ƒ—
 
Ó¬§²³¨Ï͙ӯ©«¯¬ÏÙ½°¬³°²Ò»¯¨§µ¸¯²¨¬§µª°¬²¯§µ¨¦©ªÀ²¯««
§²³¤¯§«®¬¯³º»‹¬¯«¥°²«¯¨°¨°¥©ª§µ°ª®µ§¬¦£¥°¨¯²«©´¯¤¯³©ª§
¨©°²©²¨¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£
ª¸×ÁÄ™¥™¤®¸¦®
Ÿ  Å– ‘\t˜††ƒ†ŸŸ

¸°µ¯¤§²Ã¢™½°¬³°²Ò»™Ó¯©«¯¬Ï﨧µÓ§«¯µ©²¯¬©«À±§ª¨°¬«
±°¬¨¦¯³¯´¯µ°¥¤¯²¨°±¥¬©¤§¬£°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§©²¨¦¯»ª®
µ§¬Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£
ª¸×ÁÄ™¥™¤®¸¦®
Ÿ  Å– \t˜
—–ƒ—–‘
Ÿ
Ó¬§²³¨Ï͙ӯ©«¯¬ÏÙߧ««Ò﨧µ¸¯²¨¬§µª°¬²¯§µ¨¦©ªÀ²¯««
©²¨¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²¼¬¯§¨¤¯²¨Ž¨®³£ »Ô¼Ž\t
ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  Å –  \t˜††Þƒ†––

õ¯À«¯¯´Â¿™¢©¨´©²ºÓº²±µ®¯²ª¯°±¨¦¯¨¦©ªÀ²¯««°±¨¦¯ª°¬²¯§°²
¨¦¯µ¯´¯µ°±©²¨¬§°ª®µ§¬¥¬¯««®¬¯§²³¥¬°¹²°«©«±°¬¥¬©¤§¬£°¥¯²ƒ§²¹µ¯
¹µ§®ª°¤§
¬º×˜®²œ²¼¤®ÁÄ™¥™¤®¸¦®¦£ž
Ÿ  –Ő˜ 

½°¬³°²Ò»™Ó¯©«¯¬ÏÙӬ§²³¨Ïͯ¨§µ¼¦¯»ª®µ§¬Ô£¥¯¬¨¯²«©°²
¼¬¯§¨¤¯²¨Ž¨®³£˜¶§«¯µ©²¯±§ª¨°¬«¨¦§¨¥¬¯³©ª¨¨¦¯°²«¯¨°±¥¬©¤§¬£
°¥¯²ƒ§²¹µ¯¹µ§®ª°¤§
ª›¼™ÁÄ™¥™¤®¸¦®
Ÿ  ŸÅŸ  —\t˜†ƒ†Ÿ 
\f / Received / 28.12.2017

Приложенные файлы

  • pdf 43252837
    Размер файла: 260 kB Загрузок: 0

Добавить комментарий